Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001628280-26-046936
Filing Date
2026-07-02
Accepted
2026-07-02 16:27:52
Documents
5
Period of Report
2026-07-01

Document Format Files

Seq Description Document Type Size
1 6-K telix-6kforprostactglobalp.htm 6-K 23016
2 EX-99.1 a20260702fdaalignmentpro.htm EX-99.1 12445
3 GRAPHIC a20260702fdaalignmentpro001.jpg GRAPHIC 255121
4 GRAPHIC a20260702fdaalignmentpro002.jpg GRAPHIC 222045
5 GRAPHIC a20260702fdaalignmentpro003.jpg GRAPHIC 184572
  Complete submission text file 0001628280-26-046936.txt   948251
Mailing Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051
Business Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 61 3 9093 3855
Telix Pharmaceuticals Ltd (Filer) CIK: 0002007191 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-42128 | Film No.: 261151756
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)